来源：证券日报网本报讯(记者张敏)近日，港股上市公司加科思药业集团有限公司(以下简称“加科思”)发布的公告显示，非全资附属公司北京加科思新药研发有限公司(以下简称“北京加科思”)与AstraZenecaAB(以下简称“阿斯利康”)订立许可与合作协议(以下简称“许可及合作协议”)，就开发及商业化泛KRAS抑制剂JAB-23E73展开合作。根据协议条款，北京加科思将获得1亿美元的首付款，并有资格额外...
Source Link来源：证券日报网本报讯(记者张敏)近日，港股上市公司加科思药业集团有限公司(以下简称“加科思”)发布的公告显示，非全资附属公司北京加科思新药研发有限公司(以下简称“北京加科思”)与AstraZenecaAB(以下简称“阿斯利康”)订立许可与合作协议(以下简称“许可及合作协议”)，就开发及商业化泛KRAS抑制剂JAB-23E73展开合作。根据协议条款，北京加科思将获得1亿美元的首付款，并有资格额外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.